Shore received her bachelor's degree in biology from the University of Notre Dame in 1976.

[2] Shore undertakes research into fibrodysplasia ossificans progressiva (FOP), a genetic disease that causes bone tissue to form outside the skeleton, known as heterotopic ossification.

[6] The cause of the disease was traced to a single mutation in the activin A receptor, type I gene.

The authors concluded that the drug palovarotene showed promise in preventing heterotopic ossification, stating that there was "clear evidence for its encompassing therapeutic potential".

[7] As of 2015, Kaplan and Shore were the directors of the Center for Research in FOP and Related Disorders.